Apimeds Pharmaceuticals

What Apimeds Pharmaceuticals does

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) is a clinical-stage biopharmaceutical company developing Apitox (LT-100), a purified, pharmaceutical-grade honeybee venom biologic classified by the FDA as an active pharmaceutical ingredient, being investigated as a non-opioid intradermally-administered therapy for acute pain and inflammation associated with knee osteoarthritis. The asset is licensed under an exclusive patent license from Apimeds Korea (entered October 12, 2021), with a 5% royalty on EBIT due to the licensor (excluding M&A scenarios); the underlying active was originally approved and used in South Korea since 2003 under the name Apitoxin, and Apimeds is pursuing a second Phase III trial and FDA Type C alignment (meeting scheduled May 4, 2026) to support U.S. approval. The company is pre-revenue across both of its operating segments and has no commercial products to date.

Following a December 1, 2025 merger with MindWave Innovations Inc. and a concurrent $100 million PIPE financing (aggregate $120.9 million commitment, of which $10.9 million was drawn as of March 31, 2026), APUS now operates a dual-segment structure: a BioBusiness segment anchored by Apitox and held within the Lōkahi Therapeutics subsidiary formed in May 2026 under the Inscobee settlement, and a Digital Asset segment encompassing ~1,000 Bitcoin, AI-driven yield generation, and the MindWaveDAO ecosystem powered by the $NILA token. As of Q1 2026 the company reported $0 revenue, total shareholders' equity of $126.5 million, digital assets at fair value of approximately $127.8 million (Bitcoin $66.5M, Tether $6.5M, NILA Tokens $54.8M), and an accumulated deficit of approximately $45.5 million. Distribution, upon FDA approval, is planned through standard U.S. pharmaceutical wholesale and specialty pharmacy channels, with no enterprise customers, pricing disclosures, or commercial team disclosed at present.

Name

Apimeds Pharmaceuticals

Legal name

Apimeds Pharmaceuticals US, Inc.

Website

https://apimedsus.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Apimeds Pharmaceuticals (NYSE American: APUS) is a pre-revenue clinical-stage biopharma developing Apitox, a purified honeybee venom biologic for knee osteoarthritis pain, supplemented by a digital asset treasury segment acquired via its December 2025 merger with MindWave Innovations.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Clinical-stage biopharmaceutical
• Non-opioid pain therapeutics
• Biologic drug development
• Osteoarthritis treatments
• Bee venom biologics

Headquarters

HQ city

Matawan

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue company. Upon successful FDA approval and commercialization of Apitox, revenue would be generated through prescription pharmaceutical product sales in the United States. The company has a license agreement with Apimeds Korea requiring a 5% royalty on earnings before interest and taxes from Apitox sales.
2. Licensing Royalties: The company pays Apimeds Korea a 5% royalty on EBIT from sale or license of Apitox, though royalty terms do not apply in cases of share transfer, acquisition, or merger transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company developing Apitox (LT-100), a purified, pharmaceutical-grade honeybee venom-based biologic candidate classified by the FDA as an active pharmaceutical ingredient. The product is being advanced as a non-opioid intradermally administered therapy for the treatment of acute pain and inflammation associated with knee osteoarthritis, currently in Phase 3 clinical development for U.S. FDA approval under an exclusive patent license from Apimeds Korea.

Product overview

Apimeds Pharmaceuticals US is a clinical-stage biopharmaceutical company operating through two segments: a BioBusiness segment focused on developing Apitox (also referred to as LT-100), a purified honeybee venom-based biologic for non-opioid pain management, and a Digital Asset segment acquired through the December 2025 merger with MindWave Innovations. The Digital Asset segment encompasses institutional Bitcoin treasury infrastructure, AI-driven yield generation capabilities, and the MindWaveDAO ecosystem powered by the $NILA token. The combined company aims to accelerate Apimeds' clinical programs while expanding MindWave's digital asset infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• Apitox / LT-100: Purified honeybee venom-based biologic candidate for treatment of acute pain and inflammation associated with knee osteoarthritis. Originally developed and approved in South Korea as Apitoxin.
• ai² Futures Lab
• Lōkahi Therapeutics

Products and services

• Apitox (LT-100)

Quantifiable outcome

• FDA Type C meeting scheduled for May 4, 2026 to discuss LT-100 (Apitox) regulatory pathway

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Ten partnerships are on record, tiered core and minor.

• Lōkahi Therapeutics Inc.coreStrategic or Co-development Partner · 5 May 2026New subsidiary formed as part of settlement with Inscobee to advance the Apitox program. Lōkahi receives rights to Apitox IP, regulatory materials, and development data, pays $4 million to APUS, and receives 51% of common stock. Dr. Vin Menon continues as Co-CEO.
• Sungjoon ChaeminorOthers · 5 May 2026Appointed as Co-CEO effective May 4, 2026, joining Dr. Vin Menon. Chae is an architect and urban designer with experience in large-scale real estate development and urban regeneration.
• Inscobee Inc.minorStrategic or Co-development Partner · 5 May 2026Korean affiliate (KS:006490) with which Apimeds settled all outstanding disputes on May 5, 2026. Settlement resolved disputes stemming from the December 2025 merger with MindWave. Apimeds Korea is a wholly owned subsidiary of Inscobee.
• Erik EmersonminorOthers · 30 December 2025Former CEO removed from board of directors on December 30, 2025 as part of leadership changes following merger completion.
• MindWave Innovations Inc.coreStrategic or Co-development Partner · 1 December 2025Merger completed December 1, 2025 combining Apimeds' late-stage non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury and digital asset yield generation capabilities. MindWave became a wholly owned subsidiary of APUS. The merger was supported by a $100 million PIPE financing.
• University of Idaho College of Business and EconomicsminorStrategic or Co-development Partner · 10 November 2025Collaboration expanded ai² Futures Lab program to University of Idaho starting Spring 2026. Student teams work on biopharma business development projects including market and IP analysis to foster healthcare innovation.
• University of Oregon Lundquist College of BusinessminorStrategic or Co-development Partner · 14 October 2025Collaboration with ai² Futures Lab program starting Winter 2026 quarter. Initiative engages student teams in evaluating pharmaceutical assets and developing business strategies to enhance healthcare innovation.
• Nelson Mullins Riley & Scarborough LLPminorImplementation/ SI/ Consulting PartnerLegal advisor to Apimeds for the merger transaction.
• Duane Morris LLPminorImplementation/ SI/ Consulting PartnerLegal advisor to MindWave for the merger transaction.
• Apimeds KoreacoreOEM/ Whitelabel/ Licensing PartnerLicensor of Apitox technology. Company entered into business agreement August 2, 2021 to continue clinical trials and acquire FDA permits. Exclusive patent license agreement entered October 12, 2021. Pays 5% royalty on EBIT from Apitox sales (excludes merger/acquisition scenarios).

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Teva Pharmaceutical Industries: Global specialty/generic pharma with a broad pain and neurology portfolio including generic and specialty NSAIDs and migraine therapies. Comparable as a broad incumbent competing in OA and chronic pain categories.
• Sanofi: Global pharma with Synvisc/Synvisc-One hyaluronic acid injections for knee OA pain, directly overlapping the OA pain treatment paradigm. Comparable as the dominant incumbent in injectable OA pain therapies.
• Pfizer: Large-cap pharma with a long-standing osteoarthritis/pain franchise (e.g., Celebrex, Lyrica) and ongoing pain pipeline. Comparable as a broad incumbent whose pain business defines the market Apimeds would enter.
• Vertex Pharmaceuticals: Large-cap biopharma that recently launched Journavx (suzetrigine), a first-in-class non-opioid pain therapeutic. Comparable as an established player validating the non-opioid pain thesis that Apimeds is also pursuing.

Direct peers

• Collegium Pharmaceutical: Specialty pharma building a portfolio of differentiated pain and neurology therapeutics, including abuse-deterrent and non-opioid products. Comparable as a small-cap public pain-management specialty company pursuing regulated FDA pathways.
• Tonix Pharmaceuticals: Clinical-stage pharma developing therapeutics across pain, CNS, and immunology, including non-opioid pain candidates. Comparable as a small public clinical-stage company with single-asset risk in pain indications.
• Pacira BioSciences: Specialty biopharmaceutical company focused on non-opioid pain management, including the knee OA injection product Zilretta. Directly comparable as a non-opioid, injectable biologic/specialty therapy targeting the same knee OA pain prescribing audience.
• Scilex Holding: Commercial-stage specialty pharma delivering non-opioid pain therapies (e.g., ZTlido, ELYXYB) for acute and chronic pain. Comparable as a public, late-clinical/early-commercial non-opioid pain company.

Emerging players

• Regeneron Pharmaceuticals: Large biotech with deep experience developing and commercializing injectable biologics for inflammatory conditions (e.g., Dupixent, Kevzara). Comparable as a successful biologic developer in inflammation/pain indications relevant to Apitox's mechanism.
• Hyaluronic Acid OA Injection Manufacturers (e.g., Anika Therapeutics): Specialty orthopedics company offering viscosupplementation injections (e.g., Monovisc, Orthovisc) for knee OA pain. Comparable as a smaller specialty player offering a non-opioid injectable alternative for the same knee OA patient population.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apimeds Pharmaceuticals